Life Sciences Report – Implications of Brexit

Clinical Professionals and Vacancysoft

Summer 2016

In this report we examine the implications of Brexit for pharmaceutical recruitment. Our key findings are:

  • Concerns over Brexit have yet to translate into a fall in vacancy volumes in biotech
  • However once the pending EU clinical trials regulations take effect from 2017, CROs may come under pressure to move their operations
  • Regulatory costs are set to rise as the UK sets up its own framework
  • If membership of the single market can be retained combined with FTAs with other G20 countries, UK pharma could end up with a unique advantage over competition.

Yes, I want this report!

    Yes, I would like to receive more information about your products, offers, and events. I understand I can unsubscribe at any time.*

    When you provide the information above, we will use it to process your request as described in our Privacy Policy .

    Related Posts

    Quality Assurance & Engineering — UK Life Sci... How are vacancies for QA scientists and Engineers in the Life Sciences industry navigating the challenging political and economic landscape? What are ...
    Southern England — Regional Labour Market Trends, ... How are vacancies faring in the South amidst the ongoing skills shortage and the salary war? Which regions are experiencing the biggest uplifts? Which...